



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2022/S-LDF036

August 08, 2022

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeejebhoy Towers
Dalal Street, Fort, Mumbai – 400 001.

Dear Sir / Madam,

Sub: Outcome of the Board Meeting.

Ref: Scrip Code No. 524768

With reference to the above subject, we wish to inform you that the Board of Directors at their meeting held today, has approved and took on record the Un-Audited Financial Results of the Company for the first quarter ended June 30, 2022.

Please find enclosed a copy of the said Un-Audited Financial Results along with the Limited Review Report for the first quarter ended June 30, 2022. The results will also be filed in XBRL format.

The Board meeting commenced at 12.30 pm and concluded at 1:30 pm.

You are kindly requested to take same on record.
Thanking you,

Yours faithfully,
For Emmessar Biotech & Nutrition Limited

Jeyavel B. Nadar
Executive Director
DIN No.: 08163899



Encl: Financial Results & Limited Review

EMMESSAR BIOTECH & NUTRITION LIMITED
 Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State
 CIN: L24110MH1992PLC06594229

UNAUDITED FINANCIAL RESULTS (STANDLONE) FOR THE QUARTER ENDED 30TH JUNE 2022


		(Rupees in Lakhs)			
Sr. No	Particulars	Quarter Ended		Year Ended	
		30.06.2022 Unaudited	31.03.2022 Audited	30.06.2021 Unaudited	31.03.2022 Audited
PART A					
1	Revenue from Operations	20.78	14.64	2.32	36.49
2	Other Income	44.09	70.60	37.81	191.87
	Total Income (1 + 2)	64.87	85.24	40.13	228.36
PART B					
3	Expenses				
	Cost of material consumed	1.49	4.99	0.02	1.65
	Purchase of Stock-trade	7.00	0.00	0.00	11.00
	Change in Inventories of Finished goods	-0.33	0.85	0.86	-0.09
	Employee Benefit Expenses	19.36	18.05	17.95	77.31
	Depreciation & Amortisation of Assets	2.28	3.69	1.39	9.23
	Other Expenditure	8.54	8.58	11.11	36.11
	Total Expenses	38.34	36.16	31.33	135.21
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	26.53	49.08	8.80	93.15
5	Exceptional items	0.00	0.00	0.00	0
6	Profit / (loss) before tax (4 - 5)	26.53	49.08	8.80	93.15
7	Tax Expenses				
	1. Current Tax (MAT)	0.00	-19.00	0.00	-19.00
	2. Deferred Tax	-7.00	-2.22	0.00	-2.22
	3. MAT Credit available	0.00	-5.00	0.00	-5.00
	4. Excess/short provision of earlier years	0.00	-19.39	0.00	-19.39
8	Net Profit / (loss) after tax (6 - 7)	19.53	3.47	8.80	47.54
9	Other Comprehensive Income	0.00	-0.72	0.00	-0.72
10	Total comprehensive income and Other Comprehensive Income	19.53	2.75	8.80	46.82
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Earning per Shares				
	1. Basic	0.39	0.06	0.18	0.94
	2. Diluted	0.39	0.06	0.18	0.94

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 8th August 2022 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates two segments ie. Healthcare and rent on leasehold land during this quarter.
- No Investor Compliant was received for the quarter ended 30th June 2022

Mumbai
08-Aug-22

Srinivasa Raghavan Mathurakavi Ayyangar
 Managing Director
 DIN: 00090266



EMMESSAR BIOTECH & NUTRITION LIMITED

Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229

Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2022

[Rs. In Lakhs]

		Quarter Ended				Year Ended	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022		
		Unaudited	Audited	Unaudited	Audited		
1	I. Segment Revenue						
a	Healthcare	20.78	14.64	2.32		36.49	
b	Rent on Leasehold Land	37.16	37.16	33.78		138.51	
c	Others	6.93	33.44	4.03		53.36	
	Total:	64.87	85.24	40.13		228.36	
	Less: Inter Segment Revenue	-	-	-		-	
	Net Sales / Income from Operations	64.87	85.24	40.13		228.36	
2	Segment Results (Profit / Loss) tax						
a	Healthcare	11.86	8.13	1.44		22.60	
b	Rent on Leasehold Land	36.93	37.16	33.55		138.51	
c	Others	6.93	33.44	4.03		53.36	
	Total:	55.72	78.73	39.02		214.47	
	Less:						
	Interest	-	-	-		-	
	Other Unallocable Expenditure (Net off)	29.19	29.65	30.22		121.32	
	Total Profit before Tax & Exceptional items	26.53	49.08	8.80		93.15	
3	Capital Employed (Segment Assets - Segment Liabilities)						
a	Healthcare	6.55	3.78	6.45		3.78	
b	Leasehold Land	-0.02	0.21	0.91		0.21	
c	Others	634.90	583.79	479.20		583.79	
	Total:	641.43	587.78	486.56		587.78	

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 8th August 2022

Mumbai
08-Aug-22

By order of the Board
Srinivasa Raghavan Mathurakavi Ayyangar
Managing Director
DIN: 00090266



Tel : 2200 4465, 2206 7440
Fax : 91-22- 2200 0649
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.

CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai – 400 020

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF

Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter ended June 30, 2022.
2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: August 8, 2022

**For V. Sankar Aiyar & Co.,
Chartered Accountants
(FRN. 109208W)**

Asha
Jayantibhai Patel
Digitally signed
by Asha
Jayantibhai Patel
Date: 2022.08.08
13:40:13 +05'30'

Asha Patel
Partner
(Membership No. 166048)
UDIN: 22166048AONMYR2166